TD Cowen on Ascendis Pharma (ASND): 'Physician Survey Shows Smooth Sailing For Yorvipath'
Tweet Send to a Friend
TD Cowen analyst Yaron Werber reiterated a Buy rating and $325.00 price target on Ascendis Pharma (NASDAQ: ASND).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
